1. Home
  2. VERO vs VIVS Comparison

VERO vs VIVS Comparison

Compare VERO & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VERO
  • VIVS
  • Stock Information
  • Founded
  • VERO N/A
  • VIVS 2007
  • Country
  • VERO Canada
  • VIVS United States
  • Employees
  • VERO N/A
  • VIVS 13
  • Industry
  • VERO Medical/Dental Instruments
  • VIVS Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • VERO Health Care
  • VIVS Health Care
  • Exchange
  • VERO Nasdaq
  • VIVS Nasdaq
  • Market Cap
  • VERO 4.5M
  • VIVS 4.7M
  • IPO Year
  • VERO N/A
  • VIVS N/A
  • Fundamental
  • Price
  • VERO $2.40
  • VIVS $1.80
  • Analyst Decision
  • VERO
  • VIVS
  • Analyst Count
  • VERO 0
  • VIVS 0
  • Target Price
  • VERO N/A
  • VIVS N/A
  • AVG Volume (30 Days)
  • VERO 31.4K
  • VIVS 50.5K
  • Earning Date
  • VERO 08-14-2025
  • VIVS 08-12-2025
  • Dividend Yield
  • VERO N/A
  • VIVS N/A
  • EPS Growth
  • VERO N/A
  • VIVS N/A
  • EPS
  • VERO N/A
  • VIVS N/A
  • Revenue
  • VERO $60,107,000.00
  • VIVS $142,000.00
  • Revenue This Year
  • VERO N/A
  • VIVS $42.38
  • Revenue Next Year
  • VERO $7.47
  • VIVS $15.42
  • P/E Ratio
  • VERO N/A
  • VIVS N/A
  • Revenue Growth
  • VERO N/A
  • VIVS 94.52
  • 52 Week Low
  • VERO $2.10
  • VIVS $1.41
  • 52 Week High
  • VERO $14.50
  • VIVS $21.96
  • Technical
  • Relative Strength Index (RSI)
  • VERO 45.57
  • VIVS N/A
  • Support Level
  • VERO $2.25
  • VIVS N/A
  • Resistance Level
  • VERO $2.49
  • VIVS N/A
  • Average True Range (ATR)
  • VERO 0.11
  • VIVS 0.00
  • MACD
  • VERO -0.01
  • VIVS 0.00
  • Stochastic Oscillator
  • VERO 31.98
  • VIVS 0.00

About VERO Venus Concept Inc.

Venus Concept Inc is a medical technology company. It develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company's products include NeoGraft, Venus Viva, Venus Legacy, Venus Versa, Venus Velocity, Venus Bliss, ARTAS systems, and others. The company provides medical devices and treatments for hair, body, and skin-related problems. It generates a majority of its revenue from the United States.

About VIVS VivoSim Labs Inc. Common Stock

VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.

Share on Social Networks: